NCT02242942 · OUTCOME

Percentage of Participants With CD19 + /CD5+ B Cells or CD14+ Monocytes

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia · Source last updated 2025-11-06

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Baseline up to approximately 10.75 years

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2026-08
denom Units Selected: Participants
reporting Status: NOT_POSTED
time Frame: Baseline up to approximately 10.75 years
title: Percentage of Participants With CD19 + /CD5+ B Cells or CD14+ Monocytes
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice